Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Clin Microbiol Infect ; 26(6): 784.e1-784.e5, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31972317

RESUMEN

OBJECTIVES: Lomentospora prolificans is an emerging cause of serious invasive fungal infections. Optimal treatment of these infections is unknown, although voriconazole-containing treatment regimens are considered the treatment of choice. The objective of this study was to evaluate the role of combination antifungal therapy for L. prolificans infections. METHODS: We performed a retrospective review of medical records of patients with invasive L. prolificans infection diagnosed between 1 January 2008 and 9 September 2019 that were documented in the FungiScope® registry of rare invasive fungal infections. We compared clinical outcomes between antifungal treatment strategies. RESULTS: Over the study period, 41 individuals with invasive L. prolificans infection from eight different countries were documented in the FungiScope® registry. Overall, 17/40 (43%) had treatment response/stable disease and 21/40 (53%) had a fatal outcome attributed to invasive fungal infection. Combination antifungal therapy was associated with increased 28-day survival (15/24 survived versus 4/16 receiving monotherapy; p 0.027) and the combination voriconazole plus terbinafine trended to be associated with higher rates of treatment success (10/16, 63%, 95% CI 35%-85%) compared with other antifungal treatment regimens (7/24, 29%, 95% CI 13%-51%, p 0.053). In Kaplan-Meier survival analysis there was a higher survival probability in individuals receiving the voriconazole/terbinafine combination compared with other antifungal regimens (median survival 150 days versus 17 days). CONCLUSIONS: While overall mortality was high, combination antifungal treatment, and in particular combination therapy with voriconazole plus terbinafine may be associated with improved treatment outcomes compared with other antifungal regimens for the treatment of invasive L. prolificans infections.


Asunto(s)
Antifúngicos/uso terapéutico , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Terbinafina/uso terapéutico , Voriconazol/uso terapéutico , Adulto , Anciano , Quimioterapia Combinada , Femenino , Humanos , Infecciones Fúngicas Invasoras/sangre , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Sistema de Registros , Estudios Retrospectivos , Scedosporium/efectos de los fármacos , Resultado del Tratamiento
3.
J Clin Microbiol ; 51(12): 4178-85, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24108612

RESUMEN

Although it is a severe complication in immunocompromised patients, diagnosing invasive fungal disease (IFD), especially invasive aspergillosis (IA), remains difficult. In certain clinical scenarios, examining tissue samples for identification of the infectious organism becomes important. As culture-based methods rarely yield results, the performance of an Aspergillus-specific nested PCR in fresh tissue or pleural effusion samples was evaluated. Fresh tissue (n = 59) and effusion (n = 47) specimens from 79 immunocompromised patients were subjected to an Aspergillus-specific PCR assay. Twenty-six patients had proven (n = 20) or probable (n = 6) IFD, according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria, while the remaining patients were classified as having either possible IFD (n = 30) or no IFD (n = 23). IA was identified as the underlying IFD in 21/26 proven/probable cases. PCR positivity was observed for 18/21 proven/probable and 6 possible IA cases; cases classified as no IA did not show positive signals. Patients with proven IFD (n = 5) with cultures positive for non-Aspergillus molds also had negative Aspergillus PCR results. Aspergillus PCR performance analysis yielded sensitivity and specificity values of 86% (95% confidence interval [CI], 65% to 95%) and 100% (95% CI, 86% to 100%), respectively, thus leading to a diagnostic odds ratio of >200. In this analysis, good diagnostic performance of the PCR assay for detection of IA was observed for tissue samples, while effusion samples showed lower sensitivity rates. PCR testing represents a complementary tool; a positive PCR result strengthens the likelihood of IA, whereas IA seems unlikely in cases with negative results but findings could indicate non-Aspergillus IFD. Thus, PCR testing of these specimens enhances the diagnostic capabilities.


Asunto(s)
Aspergilosis/diagnóstico , Aspergillus/aislamiento & purificación , Técnicas Microbiológicas/métodos , Técnicas de Diagnóstico Molecular/métodos , Reacción en Cadena de la Polimerasa/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Aspergillus/genética , Niño , Preescolar , Femenino , Humanos , Pulmón/microbiología , Masculino , Persona de Mediana Edad , Derrame Pleural/microbiología , Estudios Retrospectivos , Sensibilidad y Especificidad , Adulto Joven
4.
Antimicrob Agents Chemother ; 50(2): 658-66, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16436724

RESUMEN

The pharmacokinetic profiles, safety, and efficacies of different dosing schedules of posaconazole oral suspension in patients with possible, probable, and proven refractory invasive fungal infection (rIFI) or febrile neutropenia (FN) were evaluated in a multicenter, open-label, parallel-group study. Sixty-six patients with FN and 32 patients with rIFI were randomly assigned to one of three posaconazole regimens: 200 mg four times a day (q.i.d.) for nine doses, followed by 400 mg twice a day (b.i.d.); 400 mg q.i.d. for nine doses, followed by 600 mg b.i.d.; or 800 mg b.i.d. for five doses, followed by 800 mg once a day (q.d.). Therapy was continued for up to 6 months in patients with rIFI or until neutrophil recovery occurred in patients with FN. The 400-mg-b.i.d. dose provided the highest overall mean exposure, with 135% (P = 0.0004) and 182% (P < 0.0001) greater exposure than the 600-mg-b.i.d. and 800-mg-q.d. doses, respectively. However, exposure in allogeneic bone marrow transplant (BMT) recipients (n = 12) was 52% lower than in non-BMT patients. Treatment-related adverse events (occurring in 24% of patients) were mostly gastrointestinal in nature. Twenty-four percent of patients had adverse events leading to premature discontinuation (none were treatment related). In efficacy-evaluable patients, successful clinical response was observed in 43% with rIFI (56% of patients receiving 400 mg b.i.d., 17% receiving 600 mg b.i.d., and 50% receiving 800 mg q.d.) and 77% with FN (74% receiving 400 mg b.i.d., 78% receiving 600 mg b.i.d., and 81% receiving 800 mg q.d.). Posaconazole is well tolerated and absorbed. Divided doses of 800 mg (400 mg b.i.d.) provide the greatest posaconazole exposure.


Asunto(s)
Antifúngicos/farmacocinética , Fiebre/tratamiento farmacológico , Micosis/tratamiento farmacológico , Neutropenia/complicaciones , Triazoles/farmacocinética , Adulto , Anciano , Trasplante de Médula Ósea , Femenino , Humanos , Masculino , Persona de Mediana Edad , Triazoles/efectos adversos
5.
Bone Marrow Transplant ; 35(10): 1011-8, 2005 May.
Artículo en Inglés | MEDLINE | ID: mdl-15821768

RESUMEN

A total of 155 patients with acute myeloid leukemia (AML) received hematopoietic stem cell transplants from unrelated donors after standard conditioning. Clinical outcome after the use of two different antithymocyte globulins for the prevention of graft-versus-host disease (GvHD) was analyzed in a retrospective study as follows: rabbit ATG (Thymoglobulin Sangstat/Genzyme, n=49, median age 42 years, 53% in CR, further ATG-S); rabbit ATG (ATG-Fresenius, n=38, median age 42 years, 58% in CR, further ATG-F) or no ATG (n=68, median age 36 years, 55% in CR). The groups were comparable regarding disease status at transplant, age, CMV status and cytogenetics. Grade III-IV acute GvHD was found in 15% in the ATG and 27% in the no ATG group (P=0.44). The most important independent risk factors for chronic GvHD (cGvHD) were the use of ATG, disease status at transplant and conditioning. cGvHD developed significantly more frequently in no ATG group. With the median follow-up of 34 months, the 5-year survival is 42% for those transplanted in CR. To conclude, these data demonstrate that the transplants performed in CR, with ATG, are associated with a good outcome, low incidence of cGvHD and no increase of relapse.


Asunto(s)
Suero Antilinfocítico/uso terapéutico , Enfermedad Injerto contra Huésped/prevención & control , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Leucemia Mieloide Aguda/terapia , Adolescente , Adulto , Suero Antilinfocítico/efectos adversos , Femenino , Humanos , Leucemia Mieloide Aguda/mortalidad , Masculino , Persona de Mediana Edad , Análisis Multivariante , Recurrencia , Estudios Retrospectivos
6.
Ugeskr Laeger ; 163(32): 4195-7, 2001 Aug 06.
Artículo en Danés | MEDLINE | ID: mdl-11510237

RESUMEN

INTRODUCTION: The aim of the study was to describe the clinical, radiological, and functional results of intramedullary nailing of deformities in the lower extremities of children with osteogenesis imperfecta after the use of multiple osteotomies and non-telescoping rods (rush pins). MATERIAL AND METHODS: Eight children with osteogenesis imperfecta, who consecutively underwent surgery during 1991-1994, were entered in the study. RESULTS: Sixteen operations were performed on eight children: 12 on the femur and four on the tibia. Like others, we found a high complication rate, 50%. Radiological correction of angular deformities was good. The functional outcome was satisfactory and the patients were satisfied. CONCLUSION: Correction and stabilisation of deformities in the lower extremities in children with osteogenesis imperfecta with the use of non-telescoping rods is an acceptable method of decreasing fractures and allowing most formerly non-ambulatory children to walk. Furthermore, the cosmetics were improved.


Asunto(s)
Clavos Ortopédicos , Fémur/cirugía , Osteogénesis Imperfecta/cirugía , Osteotomía/métodos , Tibia/cirugía , Adolescente , Niño , Preescolar , Femenino , Fémur/diagnóstico por imagen , Estudios de Seguimiento , Marcha , Humanos , Masculino , Osteogénesis Imperfecta/diagnóstico por imagen , Osteogénesis Imperfecta/fisiopatología , Satisfacción del Paciente , Radiografía , Tibia/diagnóstico por imagen
7.
J Biomol NMR ; 20(1): 15-21, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11430751

RESUMEN

Protein docking algorithms can be used to study the driving forces and reaction mechanisms of docking processes. They are also able to speed up the lengthy process of experimental structure elucidation of protein complexes by proposing potential structures. In this paper, we are discussing a variant of the protein-protein docking problem, where the input consists of the tertiary structures of proteins A and B plus an unassigned one-dimensional 1H-NMR spectrum of the complex AB. We present a new scoring function for evaluating and ranking potential complex structures produced by a docking algorithm. The scoring function computes a 'theoretical' 1H-NMR spectrum for each tentative complex structure and subtracts the calculated spectrum from the experimental one. The absolute areas of the difference spectra are then used to rank the potential complex structures. In contrast to formerly published approaches (e.g. [Morelli et al. (2000) Biochemistry, 39, 2530-2537]) we do not use distance constraints (intermolecular NOE constraints). We have tested the approach with four protein complexes whose three-dimensional structures are stored in the PDB data bank (Bernstein et al., 1977) and whose 1H-NMR shift assignments are available from the BMRB database. The best result was obtained for an example, where all standard scoring functions failed completely. Here, our new scoring function achieved an almost perfect separation between good approximations of the true complex structure and false positives.


Asunto(s)
Algoritmos , Resonancia Magnética Nuclear Biomolecular/métodos , Unión Proteica , Estructura Terciaria de Proteína , Proteínas S100 , Animales , Proteínas de Unión al Calcio/química , ATPasas Transportadoras de Calcio/química , Calmodulina/química , Simulación por Computador , Reacciones Falso Positivas , Sustancias Macromoleculares , Modelos Moleculares , Factores de Crecimiento Nervioso/química , Fragmentos de Péptidos/química , Proteínas Quinasas/química , Subunidad beta de la Proteína de Unión al Calcio S100 , Termodinámica
8.
J Org Chem ; 66(6): 2078-84, 2001 Mar 23.
Artículo en Inglés | MEDLINE | ID: mdl-11300904

RESUMEN

The synthesis of racemic 2'-(trimethylammonium)ethyl-3-hexadecyloxy-2-fluoro-2-(methoxymethyl)prop-1-yl-phosphate (6), a fluorinated analogue of an anticancer active ether lipid 5 was realized with 3% overall yield in a nine-step synthesis starting from 2-methylene-1,3-propanediol (7) using a bromofluorination as the key step. Both enantiomers of the precursor 8 of the ether lipid 6 were synthesized by lipase-catalyzed desymmetrization of the diacetate 17, either by hydrolysis (83% ee) or by lipase-catalyzed acetylation of the diol 22 (82% ee). The antitumor activity of 6 has been found in an in vivo model of the methylcholanthrene-induced fibrosarcoma of mice.


Asunto(s)
Antineoplásicos/síntesis química , Flúor/química , Lípidos/síntesis química , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Ensayos de Selección de Medicamentos Antitumorales , Éteres/química , Lípidos/química , Lípidos/farmacología , Ratones , Estructura Molecular , Análisis Espectral , Células Tumorales Cultivadas
9.
Chirality ; 12(5-6): 458-63, 2000 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10824169

RESUMEN

The new chiral derivatizing agent (CDA), alpha-cyano-alpha-fluoro(2-naphthyl)-acetic acid (2-CFNA) 1 was prepared in optically pure form by chiral HPLC separation of racemic 2-CFNA methyl ester (2-CFNA Me ester) (+/-)-2. The ester was obtained by fluorination of methyl alpha-cyano(2-naphthyl)acetate with FClO3. 2-CFNA 1 has proven to be a significantly superior CDA for determination of enantiomeric excess (ee) of a primary alcohol when compared to alpha-methoxy-alpha-trifluoromethylphenylacetic acid (MTPA, Mosher's agent) and alpha-cyano-alpha-fluoro(p-tolyl)acetic acid (CFTA). The ee of (-)-3-acetoxy-2-fluoro-2-(hexadecyloxymethyl)propan-1-ol (-)-9, a fluorinated analog of anticancer active ether lipids, was determined using (+)-2-CFNA (+)-1.

10.
Acta Radiol ; 38(2): 311-2, 1997 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9093172

RESUMEN

PURPOSE: To compare 2 methods of colonic cleansing before double-contrast barium enema. A standard preparation of bisacodyl was compared with a preparation of dietary fibre (ispaghula). MATERIAL AND METHODS: The patients referred for double-contrast barium enema were randomly allocated to one of the colonic cleansing regimens. The effectiveness and patient acceptance of the preparations were evaluated. RESULTS: There was a significantly poorer colon cleanness score in the ispaghula group (p = 0.0001). Patient tolerance of the 2 regimens was not significantly different. CONCLUSION: Ispaghula alone is not sufficient as a cleansing preparation for double-contrast barium enema.


Asunto(s)
Bisacodilo/farmacología , Enema/métodos , Psyllium/farmacología , Sulfato de Bario , Colon/efectos de los fármacos , Humanos , Resultado del Tratamiento
11.
Acta Radiol ; 36(2): 193-5, 1995 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-7710802

RESUMEN

Abdominal pregnancy is a rare but life-threatening condition. The preoperative diagnosis may be difficult. When there is a suspicion of abdominal pregnancy and ultrasonographic findings are equivocal or inconclusive, MR imaging should be performed. We report a case of an abdominal pregnancy of 28 weeks' gestation diagnosed by MR.


Asunto(s)
Embarazo Abdominal/diagnóstico , Adulto , Femenino , Muerte Fetal , Humanos , Incidencia , Imagen por Resonancia Magnética , Embarazo , Embarazo Abdominal/epidemiología , Ultrasonografía Prenatal
12.
Acta Radiol ; 35(5): 426-8, 1994 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8086246

RESUMEN

We report a case of bilateral hyperplastic callus formation as a complication of fracture in a patient with osteogenesis imperfecta. The clinical and radiographic findings and the differential diagnosis are discussed.


Asunto(s)
Callo Óseo/patología , Fracturas del Fémur/patología , Osteogénesis Imperfecta/patología , Callo Óseo/diagnóstico por imagen , Niño , Fracturas del Fémur/diagnóstico por imagen , Curación de Fractura/fisiología , Humanos , Hiperplasia , Masculino , Osteogénesis Imperfecta/diagnóstico por imagen , Radiografía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...